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Abstract
Background: Children and adolescents with attention-deficit/hyperactivity disorder (ADHD) often have a co-
occurring reading disorder (RD). The purpose of this research was to assess differences between children with
ADHD without RD (ADHD-only) and those with ADHD and co-occurring RD (ADHD+RD).
Methods: Using data from the U.S. Thomson Reuter Marketscan
® Databases for the years 2005 through 2007, this
analysis compared the medical records–including patient demographics, comorbidities, and medication use–of
children (age < 18) with ADHD-only to those with ADHD+RD.
Results: Patients with ADHD+RD were significantly younger, more likely to have received a procedure code
associated with formal psychological or non-psychological testing, and more likely to have been diagnosed with
comorbid bipolar disorder, conduct disorder, or depression. They were no more likely to have received an
antidepressant, anti-manic (bipolar), or antipsychotic, and were significantly less likely to have received a
prescription for a stimulant medication.
Conclusions: Relying on a claims database, there appear to be differences in the patient characteristics,
comorbidities, and medication use when comparing children with ADHD-only to those with ADHD+RD.
Keywords: ADHD, Reading Disorder, medication use, comorbidities, patient characteristics
Background
The American Psychiatric Association’s Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV), defines reading disorder (RD) as: “[R]eading
achievement (i.e. reading accuracy, speed, or compre-
hension as measured by individually administered stan-
dardized tests) that falls substantially below that
expected given the individual’s chronological age, mea-
sured intelligence, and age-appropriate education [1].”
While the rate of RD among all school-age children in
the United States is an estimated 4% [2], up to nearly
one-third (15%-30%) of children with a diagnosis of
attention-deficit/hyperactivity disorder (ADHD) have a
co-occurring diagnosis of RD [3,4]. Research has shown
that children with ADHD and co-occurring RD (ADHD
+RD) exhibit both the deficits in the basic semantics of
language processing associated with RD and the higher-
order executive function deficits of ADHD [5-11].
Given the fact that ADHD and RD often co-occur, a
growing body of research has examined shared patho-
physiological pathways of ADHD and RD. This research
has shown that the two disorders share genetic and
environmental factors [12,13], cognitive processes
[14-16], aspects of brain anatomy and functioning [17],
and treatment interventions [18]. These and other stu-
dies have also indicated that ADHD+RD may be a
unique disorder with features not associated with either
ADHD or RD in isolation. For example, children with
ADHD and co-occurring reading or other learning dis-
orders have certain social impairments not observed in
“pure” ADHD or learning disorder groups, impairments
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any medium, provided the original work is properly cited.that may lead to a greater likelihood of peer rejection or
starting fights [19]. Still other literature indicates that
those with ADHD and co-occurring RD or other learn-
ing disorders have more pervasive attention and visuo-
motor problems than those with either ADHD without
learning disorders or learning disorders without ADHD
[7].
The purpose of the present study was to better under-
stand differences between ADHD patients with and
without co-occurring RD, using two patient groups
identified from a large managed care health care claims
database. The primary objective was to compare these
two groups on the basis of demographic characteristics,
other comorbid disorders, and pharmacological treat-
ments patterns. A secondary objective – recognizing
that use of medical billing records is a suboptimal
means of identifying children with RD – was to examine
the prevalence of a coded diagnosis RD among ADHD
patients and to compare this prevalence with other esti-
mates of RD prevalence among ADHD patients from
the literature.
Methods
Data for this study came from the U.S. Thomson Reu-
ters Marketscan
® Research Databases. These retrospec-
tive, claims databases are fully compliant with the
Health Insurance and Portability Act (HIPAA) and cap-
ture person-specific clinical utilization, expenditures,
and enrollment across inpatient, outpatient, prescription
drug and carve-out services from a selection of large
employers, health plans, and government and public
organizations. The databases link paid claims and
encounter data to detailed patient information across
sites and types of providers over time and include pri-
vate sector health data from approximately 100 payers
and more than 500 million claim records. Data exam-
ined for this study spanned the years 2005 through
2007.
To be included in this study an individual had to be
identified as having either ADHD-only or ADHD+ RD.
In both groups, patients had to be diagnosed with
A D H Db a s e du p o nt h er e c e i p to fa nI C D - 9 - C Md i a g -
nostic code of 314.00 or 314.01 in the 2006 calendar
year, with the first such date identified as the index
date. In addition, individuals were required to be
younger than 18 at index date and to have continuous
insurance coverage, including prescription benefit cover-
age from 12 months prior to the index date (i.e., the
pre-period) through 12 months post index date (i.e., the
post-period). To enhance comparability between the
ADHD only and ADHD+RD cohorts, all children with a
diagnosis of mental retardation (ICD-9-CM of 317.xx,
318.xx, and 319.xx), pervasive development disorder
(ICD-9-CM of 299.xx), or developmental delays (ICD-9-
CM of 315.4x, 315.5x, 315.8x, or 315.9x) at any time
from the start of the pre-period through the end of the
post-period were excluded, as these diagnoses generally
preclude or complicate a diagnosis of RD.
Given the above criteria, patients were then categor-
ized as ADHD-only or ADHD+RD. In the ADHD-only
cohort, patients were excluded if they had a diagnosis of
RD (based upon receipt of an ICD-9-CM diagnostic
code of 315.0x) at any time from the start of the pre-
period through the end of the post-period. A total of 97,
703 children met the criteria for inclusion in the
ADHD-only cohort.
For inclusion in the ADHD+RD cohort, individuals
had to be diagnosed with ADHD and RD during the
2006 calendar year, with the first date of either diagnosis
identified as the index date. Patients with an index diag-
nosis of ADHD were required to have at least one diag-
nosis of RD over the time period from the start of the
pre-period through the end of the post-period. Similarly,
those whose index diagnosis was for RD were required
to have at least one diagnosis of ADHD from the start
of the pre-period through the end of the post period. A
total of 265 individuals were included in the ADHD+RD
cohort.
The analysis compared patient demographics, comor-
bidities, and medication use between individuals with
ADHD-only and those with ADHD+RD. Patient demo-
graphics included age, sex, region of residence, type of
insurance coverage, and type of ADHD (with or without
hyperactivity), while comorbid conditions included a
variety of neuropsychiatric and behavioral conditions.
The analysis also examined both medication use and
length of therapy for ADHD medications (long-acting
stimulants, short-acting stimulants, and non-stimulants)
and other classes of medication used to treat psychiatric
disorders (anti-depressants, anti-manic agents, antipsy-
chotics, and anxiolytics). Differences in continuous vari-
ables were examined using t-statistics, while differences
in categorical variables were examined using chi-square
statistics. All analyses were conducted using SAS, ver-
sion 9.1, and findings of P values of < 0.05 were consid-
ered statistically significant. As analyses were
exploratory in nature, no adjustment for multiple com-
parisons was undertaken.
Results
In this retrospective claims database, 0.27% of patients
with ADHD were found to have a co-occurring RD.
Patients in the ADHD-only cohort were older than
those in the ADHD+RD cohort. For example, in the
ADHD-only cohort, 49.1% of individuals were age 6-11
and 44.0% were age 12-17, while in the ADHD+RD
cohort, these percentages were 63.8% and 33.6%, respec-
tively. The majority of patients in both cohorts were
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30.6%) or an HMO (30.6% and 32.8%), and diagnosed
with ADHD with hyperactivity (70.5% and 70.9%).
Patients in the ADHD+RD cohort were more likely to
have received formal psychological testing (24.5% v
7.8%) or neuropsychological testing (5.7% v 0.9%) in a
setting that is associated with insurance reimbursement,
compared to patients with ADHD-only (see Table 1).
Comparing comorbid conditions (at the three digit
ICD-9-CM level) revealed that individuals with ADHD
+RD, compared to those with ADHD-only, were more
likely to be diagnosed with bipolar disorder (9.4% v
6.4%; P = 0.043), conduct disorder (15.5% v 11.2%; P =
0.030), depression (14.3% v 9.9%; P < 0.001), and other
learning disorders (12.8% v 3.3%; P < 0.001). Examining
subcategories of these comorbidities (e.g., the four digit
ICD-9-CM level) revealed that children with ADHD+RD
were more likely to be diagnosed with oppositional-defi-
ant disorder (11.7% v 8.0%; P = 0.028), major depressive
disorder, recurrent episode (5.3% v 3.0%; P = 0.026), and
the learning disorder of developmental speech or lan-
guage disorder (7.9% v 2.2%; P < 0.0001). There was no
difference in the two cohorts with regard to frequency
of anxiety disorders, psychotic disorders, seizure disor-
ders, or sleep disorders (see Table 2).
The two most commonly prescribed stimulant medi-
cations were extended release forms of amphetamine
mixed salts (Adderall XR) and methylphenidate (Con-
certa), while atypical antipsychotics and antidepressants
were the non-ADHD psychiatric medications most com-
monly prescribed. Relative to those with ADHD-only,
children with ADHD+RD were significantly less likely to
have received any stimulant medication (71.7% v 77.1%;
P = 0.036). They were less likely, in particular, to have
received the long-acting stimulant (Adderall XR) (23.0%
v 31.6%; P = 0.003) or a short-acting amphetamine
(4.9% v 9.5%; P = 0.011). There were no differences
between the two cohorts with regard to the frequency of
prescribing of anti-depressants, anti-manic agents, anti-
psychotics, or anxiolytics (see Table 3). While the ana-
lyses revealed significant differences in the frequency of
prescriptions for stimulant medications for children with
A D H D + R Dc o m p a r e dt ot h o s ew i t hA D H D - o n l y ,
among those prescribed such medication there was no
difference in average length of prescription over the 12
month post period. Specifically, children with ADHD-
only who were prescribed a stimulant received, on









0-5 6708 6.9 7 2.6
6-11 47970 49.1 169 63.8
12-17 43025 44.0 89 33.6
Sex
Male 69735 71.4 179 67.5
Female 27968 28.6 86 32.5
Insurance Type
Comprehensive 23216 23.8 63 23.8
Health Maintenance Organization (HMO) 29880 30.6 87 32.8
Point of Service (POS) 13715 8.4 31 11.7
Preferred Provider Organization (PPO) 29730 30.4 81 30.6
Consumer-Driven Health Plan 685 0.7 1 0.4
Missing/Unknown 477 0.5 2 0.8
U.S. Region
Northeast 5519 5.6 20 7.5
North Central 16394 16.8 32 12.1
South 26466 27.1 83 31.3
West 9357 9.6 16 6.0
Unknown 39967 40.9 114 43.0
ADHD Diagnosis Type**
ADHD Without Mention of Hyperactivity 28830 29.5 77 29.1
ADHD With Hyperactivity 68873 70.5 188 70.9
Testing***
Psychological Testing 7665 7.8 65 24.5
Neuropsychological Testing 873 0.9 15 5.7
* Age measured at index date. Mean age in the ADHD cohort was 10.8 years
(std dev = 3.5 years; median = 11 years). Mean age in the ADHD + RD cohort
was 10.2 years (std dev = 3.2 years; median = 10 years).
** Index ADHD, first ADHD in post period, or prior period diagnosis closest to
the index date, in that order.
***Psychological and Neuropsychological Testing are from prior and post
periods.
Table 2 Selected Comorbidities/Conditions
Comorbidity ADHD ADHD + RD P Value
N% N%
Anxiety Disorders 1227 1.3 4 1.5 0.580
Bipolar/Mania 6244 6.4 25 9.4 0.043
Conduct Disturbance 10984 11.2 41 15.5 0.030
Depression 9653 9.9 38 14.3 0.015
Learning Disorders 3251 3.3 34 12.8 < 0.001
Eating Disorders 134 0.1 1 0.4 0.306
Personality Disorders 120 0.1 0 0.0 1.000
Psychotic Disorders 869 0.9 5 1.9 0.085
Seizure Disorders 1097 1.1 5 1.9 0.239
Sleep Disorders 1866 1.9 1 0.4 0.069
Tics/Tourette’s 689 0.7 0 0.0 0.272
All comorbidities examined from index date through end of post-period.
Based upon univariate analyses with chi-square tests for variables with counts
of at least 5 and Fischer’s exact test if any cell had less than 5 observations.
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ADHD Medication ADHD ADHD + RD P Value
N%N %
Long-Acting Stimulants
Adderall XR 30901 31.6 61 23.0 0.003
Concerta 30976 31.7 86 32.5 0.794
Daytrana 2749 2.8 11 4.2 0.189
Focalin XR 8002 8.2 30 11.3 0.064
Metadate CD 5426 5.6 19 7.2 0.251
Metadate ER 193 0.2 0 0.0 1.000
Methylin ER 1083 1.1 5 1.9 0.227
Methylphenidate HCL ER 0 0.0 0 0.0 N/A
Methylphenidate HCL SR 0 0.0 0 0.0 N/A
Ritalin LA 4574 4.7 15 5.7 0.451
Ritalin SR 39 0.0 0 0.0 1.000
Vyvanse 262 0.3 0 0.0 1.000
Total Long-Acting 69623 71.3 181 68.3 0.288
Short-Acting Stimulants
Adderall 381 0.4 1 0.4 1.000
Amphetamine Salt Combo 9289 9.5 13 4.9 0.011
Amphetamine/Dextroamph 0 0.0 0 0.0 N/A
Cylert 0 0.0 0 0.0 N/A
Desoxyn 11 0.0 0 0.0 1.000
Dexedrine 27 0.0 0 0.0 1.000
Dexmethylphenidate HCL 109 0.1 1 0.4 0.258
Dextroamphetamine Sulfate 1231 1.3 1 0.4 0.272
Dextrostat 48 0.0 1 0.4 0.124
Dexampex 0 0.0 0 0.0 N/A
Focalin 3098 3.2 11 4.2 0.363
Methamphetamine HCL 0 0.0 0 0.0 N/A
Methylin 4986 5.1 13 4.9 0.884
Methylphenidate HCL 6701 6.9 19 7.2 0.841
Methylphenidate Hcl SA 0 0.0 0 0.0 N/A
Pemoline 10 0.0 0 0.0 1.000
Ritalin 397 0.4 2 0.8 0.293
Provigil 234 0.2 0 0.0 1.000
Total Short-Acting 22739 23.3 54 20.4 0.265
Total Stimulants 75354 77.1 190 71.7 0.036
Non-Stimulants
Atomoxetine 13732 14.1 34 12.8 0.567
Bupropion 3486 3.6 10 3.8 0.857
Alpha 2 Agonists 11296 11.6 32 12.1 0.794
Total Non-Stimulants 25506 26.1 65 24.5 0.559
Medications used to treat Other Mental Health Conditions ADHD ADHD + RD P Value
N%N %
Anti-depressants
MAOI’s 0 0.0 0 0.0 N/A
Tricyclics 1734 1.8 3 1.1 0.638
SSRI’s 9508 9.7 26 9.8 0.965
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of 6.7 months for those with ADHD+RD (P = 0.609).
Similarly, there were no differences among users of
medications between the two cohorts with regard to
average length of therapy for non-stimulants, antidepres-
sants, antipsychotics, or anxiolytics (see Table 4).
Discussion
In contrast to the literature that suggests that RD co-
occurs in 15-30% of children with ADHD [3,4], less
than 1% of children with ADHD in our study cohort
were found to have a co-occurring coded diagnosis of
RD. This almost certainly reflects the incomplete ascer-
tainment of reading disorders using administrative
claims data and highlights the fact that claims data can
provide valid epidemiologic data only to the extent that
the conditions of interest are diagnosed, managed and
reimbursed in traditional medical settings. Learning dis-
orders, including reading disorders, are typically recog-
nized and managed in an educational rather than a
medical setting, and formal assessment typically involves
the services of providers not routinely covered by tradi-
tional medical insurance (i.e., educational or clinical psy-
chologists and psychometrists, rather than psychiatrists
and other physician providers). In contrast, ADHD,
while often first recognized at home or in the classroom,
is commonly diagnosed by physicians, at least in part
because of the availability of effective pharmacological
treatment options [20]. Consequently, it should be
recognized that our results pertain to a select subset of
all children with ADHD and RD, and our findings
should be interpreted accordingly.
Despite this caveat, results of this analysis suggest that
children with ADHD+RD may differ from those with
ADHD alone in several important respects. First, a
greater proportion of the ADHD+RD children were 6-
11 years old relative to 12-17 years old (63.8% v 33.6%).
In contrast, the ADHD-only children were nearly
equally distributed in the 6-11 year old and 12-17 year
old groups (49.1% v 44.0%). This difference in age distri-
bution may reflect the fact that RD is typically identified
when reading instruction begins in school, i.e., either
Table 4 Length of Therapy-By Medication Class









Long-Acting Stimulants 69623 6.5 3.57 6.5 181 6.4 3.36 6.3 0.722
Short-Acting Stimulants 22739 4.1 3.28 3.0 54 3.2 2.88 2.0 0.053
Any Stimulant 75354 6.7 3.52 6.8 190 6.5 3.33 6.9 0.609
Non-Stimulants 25506 5.8 3.80 5.6 65 5.2 3.53 4.8 0.212
Antidepressants 14966 5.4 3.78 4.8 43 4.8 3.88 3.0 0.303
Antipsychotics 15703 6.4 3.75 6.7 52 6.3 3.67 7.3 0.863
Anxiolytics 3982 1.9 2.83 0.9 8 1.4 1.64 0.8 0.578
N is the total number of patients with non-missing days supply.
T-tests were used to examine differences in mean length of therapy between the two groups.
Table 3 Medication Use (Continued)
SNRI’s 772 0.8 1 0.4 0.729
Other 5105 5.2 18 6.8 0.252
Total Antidepressants 14966 15.3 43 16.2 0.682
Antimanic (bipolar) agents 7208 7.4 21 7.9 0.734
Antipsychotics
Typical 444 0.5 0 0.0 0.638
Atypical 15593 16.0 52 19.6 0.104
Total Antipsychotics 15703 16.1 52 19.6 0.116
Anxiolytics
Benzodiazepines 1807 1.8 3 1.1 0.643
Others 2388 2.4 5 1.9 0.557
Total Anxiolytics 3982 4.1 8 3.0 0.385
All comorbidties examined from index date through end of post-period.
Based upon univariate analyses with chi-square tests for variables with counts of at least 5 and Fischer’s exact test if any cell had less than 5 observations.
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Page 5 of 8the end of kindergarten or the beginning of first grade
[1,21], whereas ADHD requires the identification of
symptoms in multiple domains of functioning (e.g.,
home, school) before it can be diagnosed [1]. Therefore,
as the DSM-IV states: “[M]any individuals are diagnosed
[with ADHD] after the symptoms have been present for
a number of years, especially in the case of individuals
with Predominantly Inattentive Type [1].” Alternatively,
this age discrepancy could be a function of the non-
representativeness of our ADHD+RD cohort. While we
did exclude children with mental retardation, pervasive
developmental disorder and other specific developmen-
t a ld e l a y s ,i tm a yb et h ec a s et h a to u rA D H D + R D
cohort included children with multiple and/or more
complex disorders, a subset of children more likely to
come to medical attention at an earlier age.
A large body of literature has provided evidence of a
neurological basis for RD [22-34]. In the current study,
a significantly higher percentage of ADHD+RD children
relative to ADHD-only individuals had psychological
testing (24.5% v 7.8%) and neuropsychological testing
(15% v 0.9%). This finding reflects the following recent
statement from the American Academy of Pediatrics et
al. that: “Reading involves the integration of multiple
factors related to a person’s experience, ability, and neu-
rologic functioning.... There is solid scientific evidence
that supports the neurologic basis for the phonological
coding deficit theory of reading disabilities [35].” Includ-
ing psychological or neuropsychological testing in the
process of diagnosing RD is compliant with current
medical guidelines, which state that, “Children with
learning disabilities should undergo assessments of their
health, development, hearing, and vision and, when
appropriate, medical and psychological interventions for
associated and related treatable conditions [36].”
This study also revealed significant differences
between the ADHD+RD and ADHD-only cohorts rela-
tive to comorbidities and medication use. Consistent
with previous research showing a strong association
between ADHD+RD and antisocial behavioral disorders,
including aggression, delinquency, oppositional defiant
disorder [34,37,38], as well as between RD and interna-
lizing psychiatric disorders, such as depression [34], the
ADHD+RD cohort in this study had a higher rate of
comorbid illness, including bipolar/mania, conduct dis-
turbance, oppositional defiant disorder, depression, and
learning disorders (see Table 2). Parents, educators, and
physicians should be watchful for signs of these disor-
ders in children with both ADHD and RD.
Notably, although the patients with ADHD+RD in this
study were more likely to be diagnosed with depression,
bipolar/mania, or conduct disorder, they were no more
likely to be prescribed antidepressant, anti-manic (bipo-
lar), antipsychotic, or any other type of medication.
N e i t h e rw e r et h o s ew i t hA D H D + R Dm o r el i k e l yt ob e
prescribed any of the following non-stimulant medica-
tions used in the treatment of ADHD: atomoxetine
[39,40], tricyclic antidepressants [41], or bupropion
[42,43]. Moreover, relative to the ADHD-only group, the
children with ADHD+RD were less likely to receive sti-
mulant medication, which is also commonly prescribed
for the treatment of ADHD [43]. Although the ADHD
+RD group were less likely to be prescribed stimulant
medication, those who did receive any medication had
t h es a m em e a nl e n g t ho ft h e r a p ya st h o s ei nt h e
ADHD-only cohort taking that medication (see Table 4).
The findings of this study should be interpreted in the
context of the limitations of the study design. First, the
use of diagnostic codes to identify individuals is not as
rigorous as formal diagnostic assessments for identifying
people with ADHD or RD. Because RD may be diagnosed
outside of a medical system that is associated with insur-
ance reimbursement claims, use of such a claims data-
base may preclude capturing a large segment of the
ADHD+RD population. As mentioned above, this analy-
sis found that less than 1% of individuals with ADHD
received a diagnosis of RD, while the literature suggests
that RD may co-occur in 15-30% of ADHD patients [3,4].
In addition, the study focused exclusively on patients
with medical and prescription benefit coverage. Given
these limitations, the results may not be generalizeable to
other populations. Third, as this study was descriptive in
nature, it did not control for the impact of differences in
patient characteristics (e.g., age distribution, severity of
RD or ADHD, etc.) between the two cohorts of children.
This limitation, in turn, precluded any inferences about
causality. For example, it is possible that the ADHD+RD
cohort in this study were prescribed less stimulant medi-
cation relative to the ADHD-only cohort due to the fact
that they were younger; however, this hypothesis was not
testable given the study design.
Additionally, the number of unique physician visits
was not captured in this analysis. While it appears that
children with ADHD + RD present with more medical
conditions and psychiatric comorbidities compared to
children with ADHD alone, this may be due in part to
the fact that children with ill-defined or complex devel-
opmental disorders are seen by multiple physicians and
may receive multiple “rule out” diagnoses before receiv-
ing an accurate and comprehensive assessment of their
condition. Finally, the use of medical claims data pre-
cludes the use of patient assessments; as a result, the
analysis could not examine quality of life, functioning,
or any clinical outcomes.
Conclusions
This retrospective, descriptive analysis revealed signifi-
cant differences between children with ADHD+RD and
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ADHD+RD had a higher burden of comorbidity, includ-
ing a greater likelihood of a comorbid diagnosis of bipo-
lar/mania, conduct disturbance, oppositional defiant
disorder, depression, and learning disorders. At the
same time, the children with ADHD+RD were no more
likely to have been prescribed antidepressant, anti-manic
(bipolar), antipsychotic, or any other type of medication,
and were less likely to have been prescribed stimulant
medication. These findings indicate the need for further
research into the epidemiology, treatment and associated
outcomes for children with ADHD+RD. They also indi-
cate that the burden of ADHD+RD is unique and sub-
stantial. The special characteristics of ADHD+RD
should be considered when conducting clinical evalua-
tions and targeted treatment approaches. All results
should be interpreted cautiously given the limited ability
to ascertain RD using claims data, and future research
into RD should focus on developing and using more
broadly representative datasets.
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